Vertex Pharmaceuticals (VRTX) Non Operating Income (2012 - 2025)

Vertex Pharmaceuticals' Non Operating Income history runs 14 years deep, the most recent figure standing at $6.5 million for Q4 2025.

• In Q4 2025, Non Operating Income rose 143.62% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $9.9 million (up 113.66% YoY), while the FY2025 annual figure was -$7.7 million, up 91.06% from the prior year.
• Non Operating Income was $6.5 million for Q4 2025 at Vertex Pharmaceuticals, up from -$9.8 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $42.4 million in Q3 2021 to a low of -$78.1 million in Q2 2022.
• Historically, Non Operating Income has averaged -$13.8 million across 5 years, with a median of -$12.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Non Operating Income plunged 2500.0% in 2024, then surged 157.14% in 2025.
• A 5-year view of Non Operating Income shows it stood at $7.1 million in 2021, then sank by 538.03% to -$31.1 million in 2022, then jumped by 68.49% to -$9.8 million in 2023, then plunged by 52.04% to -$14.9 million in 2024, then surged by 143.62% to $6.5 million in 2025.
• The last three Non Operating Income figures came in at $6.5 million (Q4 2025), -$9.8 million (Q3 2025), and $13.2 million (Q2 2025), per Business Quant data.